# A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

> **NCT03823300** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 658 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Faricimab
- **DRUG:** Aflibercept
- **PROCEDURE:** Sham Procedure

## Key facts

- **NCT ID:** NCT03823300
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2020-10-05
- **Final completion:** 2022-01-07
- **Target enrollment:** 658 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823300, "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03823300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*